Documents disponibles écrits par cet auteur

Classification of autism spectrum disorder from blood metabolites: Robustness to the presence of co-occurring conditions / Troy VARGASON in Research in Autism Spectrum Disorders, 77 (September 2020) 

Public ISBD [article]  in Research in Autism Spectrum Disorders > 77 (September 2020) . - 101644 Titre : Classification of autism spectrum disorder from blood metabolites: Robustness to the presence of co-occurring conditions Type de document : texte imprimé Auteurs : Troy VARGASON, Auteur ; Emily ROTH, Auteur ; Genevieve GRIVAS, Auteur ; Jennifer FERINA, Auteur ; Richard E. FRYE, Auteur ; Juergen HAHN, Auteur Article en page(s) : 101644 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Co-occurring conditions  Folate-dependent one-carbon metabolism  Transsulfuration  Multivariate analysis  Classification Index. décimale : PER Périodiques Résumé : Background Previous studies have found plasma measurements of metabolites from the folate-dependent one-carbon metabolism (FOCM) and transsulfuration (TS) pathways to be useful for differentiating individuals with autism spectrum disorder (ASD) from their typically developing peers. However, ASD is heterogeneous due to wide variation in the presence of co-occurring behavioral and medical conditions, and it is unknown how these conditions influence the ability to identify ASD based on FOCM/TS metabolites. Method This study employs a previously developed multivariate model that makes use of five FOCM/TS measurements (S-adenosylmethionine/S-adenosylhomocysteine, glutamylcysteine, glutathione disulfide, free cystine/free cysteine, and percent oxidized glutathione) to distinguish children with ASD from typically developing children. The model is used here to evaluate an independent cohort of individuals having ASD with diagnosed co-occurring conditions (age range 2–17 years old) and assess classifier performance in the presence/absence of these conditions. The four categories of co-occurring conditions considered were allergic disorders, gastrointestinal disorders, immune/metabolic disorders, and neurological disorders. All data were collected and retrospectively analyzed from previous clinical studies. Results The model was able to identify 124 of 131 participants with ASD (94.7 %) correctly regardless of co-occurring condition status. Model performance was generally not sensitive to the absence or presence of most co-occurring conditions, with the exceptions of ever/never having allergies or gastrointestinal symptoms, or currently (not) having any condition, all of which had minor impacts on model prediction accuracy. Conclusion The results of this exploratory study suggest that a FOCM/TS-based classifier for diagnosing ASD may potentially be robust to variations in co-occurring conditions and potentially applicable across ASD subtypes. Larger, more comprehensive follow-up studies with typically developing and/or developmentally delayed control groups are required to provide a more conclusive assessment of classifier robustness to co-occurring conditions. En ligne : https://doi.org/10.1016/j.rasd.2020.101644 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4329 [article] Classification of autism spectrum disorder from blood metabolites: Robustness to the presence of co-occurring conditions [texte imprimé] / Troy VARGASON, Auteur ; Emily ROTH, Auteur ; Genevieve GRIVAS, Auteur ; Jennifer FERINA, Auteur ; Richard E. FRYE, Auteur ; Juergen HAHN, Auteur . - 101644. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 77 (September 2020) . - 101644 Mots-clés : Autism spectrum disorder  Co-occurring conditions  Folate-dependent one-carbon metabolism  Transsulfuration  Multivariate analysis  Classification Index. décimale : PER Périodiques Résumé : Background Previous studies have found plasma measurements of metabolites from the folate-dependent one-carbon metabolism (FOCM) and transsulfuration (TS) pathways to be useful for differentiating individuals with autism spectrum disorder (ASD) from their typically developing peers. However, ASD is heterogeneous due to wide variation in the presence of co-occurring behavioral and medical conditions, and it is unknown how these conditions influence the ability to identify ASD based on FOCM/TS metabolites. Method This study employs a previously developed multivariate model that makes use of five FOCM/TS measurements (S-adenosylmethionine/S-adenosylhomocysteine, glutamylcysteine, glutathione disulfide, free cystine/free cysteine, and percent oxidized glutathione) to distinguish children with ASD from typically developing children. The model is used here to evaluate an independent cohort of individuals having ASD with diagnosed co-occurring conditions (age range 2–17 years old) and assess classifier performance in the presence/absence of these conditions. The four categories of co-occurring conditions considered were allergic disorders, gastrointestinal disorders, immune/metabolic disorders, and neurological disorders. All data were collected and retrospectively analyzed from previous clinical studies. Results The model was able to identify 124 of 131 participants with ASD (94.7 %) correctly regardless of co-occurring condition status. Model performance was generally not sensitive to the absence or presence of most co-occurring conditions, with the exceptions of ever/never having allergies or gastrointestinal symptoms, or currently (not) having any condition, all of which had minor impacts on model prediction accuracy. Conclusion The results of this exploratory study suggest that a FOCM/TS-based classifier for diagnosing ASD may potentially be robust to variations in co-occurring conditions and potentially applicable across ASD subtypes. Larger, more comprehensive follow-up studies with typically developing and/or developmentally delayed control groups are required to provide a more conclusive assessment of classifier robustness to co-occurring conditions. En ligne : https://doi.org/10.1016/j.rasd.2020.101644 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4329

Effectiveness of Methylcobalamin and Folinic Acid Treatment on Adaptive Behavior in Children with Autistic Disorder Is Related to Glutathione Redox Status / Richard E. FRYE in Autism Research and Treatment, (November 2013) 

Public ISBD [article]  in Autism Research and Treatment > (November 2013) . - 9 p. Titre : Effectiveness of Methylcobalamin and Folinic Acid Treatment on Adaptive Behavior in Children with Autistic Disorder Is Related to Glutathione Redox Status Type de document : texte imprimé Auteurs : Richard E. FRYE, Auteur ; Stepan MELNYK, Auteur ; George J. FUCHS, Auteur ; Tyra REID, Auteur ; Stefanie JERNIGAN, Auteur ; Oleksandra PAVLIV, Auteur ; Amanda HUBANKS, Auteur ; David W. GAYLOR, Auteur ; Laura WALTERS, Auteur ; S. Jill JAMES, Auteur Année de publication : 2013 Article en page(s) : 9 p. Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Treatments targeting metabolic abnormalities in children with autism are limited. Previously we reported that a nutritional treatment significantly improved glutathione metabolism in children with autistic disorder. In this study we evaluated changes in adaptive behaviors in this cohort and determined whether such changes are related to changes in glutathione metabolism. Thirty-seven children diagnosed with autistic disorder and abnormal glutathione and methylation metabolism were treated with twice weekly 75?µg/Kg methylcobalamin and twice daily 400?µg folinic acid for 3 months in an open-label fashion. The Vineland Adaptive Behavior Scale (VABS) and glutathione redox metabolites were measured at baseline and at the end of the treatment period. Over the treatment period, all VABS subscales significantly improved with an average effect size of 0.59, and an average improvement in skills of 7.7 months. A greater improvement in glutathione redox status was associated with a greater improvement in expressive communication, personal and domestic daily living skills, and interpersonal, play-leisure, and coping social skills. Age, gender, and history of regression did not influence treatment response. The significant behavioral improvements observed and the relationship between these improvements to glutathione redox status suggest that nutritional interventions targeting redox metabolism may benefit some children with autism. En ligne : http://dx.doi.org/10.1155/2013/609705 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=2282 [article] Effectiveness of Methylcobalamin and Folinic Acid Treatment on Adaptive Behavior in Children with Autistic Disorder Is Related to Glutathione Redox Status [texte imprimé] / Richard E. FRYE, Auteur ; Stepan MELNYK, Auteur ; George J. FUCHS, Auteur ; Tyra REID, Auteur ; Stefanie JERNIGAN, Auteur ; Oleksandra PAVLIV, Auteur ; Amanda HUBANKS, Auteur ; David W. GAYLOR, Auteur ; Laura WALTERS, Auteur ; S. Jill JAMES, Auteur . - 2013 . - 9 p. Langues : Anglais (eng) in Autism Research and Treatment > (November 2013) . - 9 p. Index. décimale : PER Périodiques Résumé : Treatments targeting metabolic abnormalities in children with autism are limited. Previously we reported that a nutritional treatment significantly improved glutathione metabolism in children with autistic disorder. In this study we evaluated changes in adaptive behaviors in this cohort and determined whether such changes are related to changes in glutathione metabolism. Thirty-seven children diagnosed with autistic disorder and abnormal glutathione and methylation metabolism were treated with twice weekly 75?µg/Kg methylcobalamin and twice daily 400?µg folinic acid for 3 months in an open-label fashion. The Vineland Adaptive Behavior Scale (VABS) and glutathione redox metabolites were measured at baseline and at the end of the treatment period. Over the treatment period, all VABS subscales significantly improved with an average effect size of 0.59, and an average improvement in skills of 7.7 months. A greater improvement in glutathione redox status was associated with a greater improvement in expressive communication, personal and domestic daily living skills, and interpersonal, play-leisure, and coping social skills. Age, gender, and history of regression did not influence treatment response. The significant behavioral improvements observed and the relationship between these improvements to glutathione redox status suggest that nutritional interventions targeting redox metabolism may benefit some children with autism. En ligne : http://dx.doi.org/10.1155/2013/609705 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=2282

The lifetime social cost of autism: 1990–2029 / Janet CAKIR in Research in Autism Spectrum Disorders, 72 (April 2020) 

Public ISBD [article]  in Research in Autism Spectrum Disorders > 72 (April 2020) . - p.101502 Titre : The lifetime social cost of autism: 1990–2029 Type de document : texte imprimé Auteurs : Janet CAKIR, Auteur ; Richard E. FRYE, Auteur ; Stephen J. WALKER, Auteur Article en page(s) : p.101502 Langues : Anglais (eng) Mots-clés : Autism  Autism cost  Autism rates  Autism policy  US autism  ASD Index. décimale : PER Périodiques Résumé : This cost of illness analysis computes a baseline and future estimate of lifetime social costs associated with autism spectrum disorder (ASD) for the 50 states in the United States (US). The number of cases of ASD are estimated, then multiplied by annual direct and indirect medical and non-medical costs identified in the peer-reviewed literature. This amount is then extrapolated across the number of years each cost type is expected to be incurred to calculate a total lifetime cost for each state in the US from 1990–2019, and to project future cost for 2020–2029. From 1990–2019, there have been an estimated 2 million new cases of (ASD), with social costs of more than $7 trillion. If the future prevalence of ASD remains unchanged over the next decade, there will be an estimated additional 1 million new cases, resulting in an additional $4 trillion to the United States in social costs, however if the rate of increase in prevalence continues, costs could reach nearly $15 trillion by 2029. The financial burden of ASD is significant and identifying the modifiable causes of ASD has the potential to provide tangible benefits. En ligne : https://doi.org/10.1016/j.rasd.2019.101502 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4209 [article] The lifetime social cost of autism: 1990–2029 [texte imprimé] / Janet CAKIR, Auteur ; Richard E. FRYE, Auteur ; Stephen J. WALKER, Auteur . - p.101502. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 72 (April 2020) . - p.101502 Mots-clés : Autism  Autism cost  Autism rates  Autism policy  US autism  ASD Index. décimale : PER Périodiques Résumé : This cost of illness analysis computes a baseline and future estimate of lifetime social costs associated with autism spectrum disorder (ASD) for the 50 states in the United States (US). The number of cases of ASD are estimated, then multiplied by annual direct and indirect medical and non-medical costs identified in the peer-reviewed literature. This amount is then extrapolated across the number of years each cost type is expected to be incurred to calculate a total lifetime cost for each state in the US from 1990–2019, and to project future cost for 2020–2029. From 1990–2019, there have been an estimated 2 million new cases of (ASD), with social costs of more than $7 trillion. If the future prevalence of ASD remains unchanged over the next decade, there will be an estimated additional 1 million new cases, resulting in an additional $4 trillion to the United States in social costs, however if the rate of increase in prevalence continues, costs could reach nearly $15 trillion by 2029. The financial burden of ASD is significant and identifying the modifiable causes of ASD has the potential to provide tangible benefits. En ligne : https://doi.org/10.1016/j.rasd.2019.101502 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4209

Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects / J. Mick TILFORD in Journal of Autism and Developmental Disorders, 45-11 (November 2015) 

Public ISBD [article]  in Journal of Autism and Developmental Disorders > 45-11 (November 2015) . - p.3613-3623 Titre : Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects Type de document : texte imprimé Auteurs : J. Mick TILFORD, Auteur ; Nalin PAYAKACHAT, Auteur ; Karen A. Kuhlthau, Auteur ; Jeffrey M. PYNE, Auteur ; Erica KOVACS, Auteur ; Jayne BELLANDO, Auteur ; D. Keith WILLIAMS, Auteur ; Werner B. F. Brouwer, Auteur ; Richard E. FRYE, Auteur Article en page(s) : p.3613-3623 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Child health  Caregiver health  Child sleep habits  Quality adjusted life year  Cost-effectiveness analysis Index. décimale : PER Périodiques Résumé : Sleep problems in children with autism spectrum disorders (ASD) are under-recognized and under-treated. Identifying treatment value accounting for health effects on family members (spillovers) could improve the perceived cost-effectiveness of interventions to improve child sleep habits. A prospective cohort study (N = 224) was conducted with registry and postal survey data completed by the primary caregiver. We calculated quality of life outcomes for the child and the primary caregiver associated with treatments to improve sleep in the child based on prior clinical trials. Predicted treatment effects for melatonin and behavioral interventions were similar in magnitude for the child and for the caregiver. Accounting for caregiver spillover effects associated with treatments for the child with ASD increases treatment benefits and improves cost-effectiveness profiles. En ligne : http://dx.doi.org/10.1007/s10803-015-2507-5 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=2704 [article] Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects [texte imprimé] / J. Mick TILFORD, Auteur ; Nalin PAYAKACHAT, Auteur ; Karen A. Kuhlthau, Auteur ; Jeffrey M. PYNE, Auteur ; Erica KOVACS, Auteur ; Jayne BELLANDO, Auteur ; D. Keith WILLIAMS, Auteur ; Werner B. F. Brouwer, Auteur ; Richard E. FRYE, Auteur . - p.3613-3623. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 45-11 (November 2015) . - p.3613-3623 Mots-clés : Autism spectrum disorder  Child health  Caregiver health  Child sleep habits  Quality adjusted life year  Cost-effectiveness analysis Index. décimale : PER Périodiques Résumé : Sleep problems in children with autism spectrum disorders (ASD) are under-recognized and under-treated. Identifying treatment value accounting for health effects on family members (spillovers) could improve the perceived cost-effectiveness of interventions to improve child sleep habits. A prospective cohort study (N = 224) was conducted with registry and postal survey data completed by the primary caregiver. We calculated quality of life outcomes for the child and the primary caregiver associated with treatments to improve sleep in the child based on prior clinical trials. Predicted treatment effects for melatonin and behavioral interventions were similar in magnitude for the child and for the caregiver. Accounting for caregiver spillover effects associated with treatments for the child with ASD increases treatment benefits and improves cost-effectiveness profiles. En ligne : http://dx.doi.org/10.1007/s10803-015-2507-5 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=2704